Rural residence and chronic obstructive pulmonary disease exacerbations: Analysis of the SPIROMICS cohort by Burkes, R.M. et al.
ORIGINAL RESEARCH
Rural Residence and Chronic Obstructive Pulmonary
Disease Exacerbations
Analysis of the SPIROMICS Cohort
Robert M. Burkes1, Amanda J. Gassett2, Agathe S. Ceppe3, Wayne Anderson3, Wanda K. O’Neal3,
Prescott G. Woodruff4, Jerry A. Krishnan5, R. Graham Barr6, MeiLan K. Han7, Fernando J. Martinez8,
Alejandro P. Comellas9, Allison A. Lambert10, Joel D. Kaufman2, Mark T. Dransfield11, J. Michael Wells11,
Richard E. Kanner12, Robert Paine III12, Eugene R. Bleecker13, Laura M. Paulin14, Nadia N. Hansel14, and
M. Bradley Drummond1; on behalf of the SPIROMICS Investigators
1Division of Pulmonary Diseases and Critical Medicine, and 3Marsico Lung Institute/Cystic Fibrosis Research Center, Department of
Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 2Department of Environmental and Occupational Health
Sciences, School of Public Health, and 10Division of Pulmonary and Critical Care, University of Washington, Seattle, Washington; 4Division
of Pulmonary, Critical Care, Sleep and Allergy, Department of Medicine and Cardiovascular Research Institute, University of California San
Francisco, School of Medicine, San Francisco, California; 5Division of Pulmonary, Critical Care, Sleep, and Allergy, University of Illinois,
Chicago, Illinois; 6Department of Medicine, Columbia University Medical Center, New York, New York; 7Division of Pulmonary and Critical
Care Medicine, University of Michigan Health System, Ann Arbor, Michigan; 8Department of Medicine, Weill Cornell Medical College,
New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, New York; 9Division of Pulmonary and Critical Care, University
of Iowa, Iowa City, Iowa; 11Division of Pulmonary and Critical Care, University of Alabama at Birmingham, Birmingham,
Alabama; 12Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Utah, Salt Lake City,
Utah; 13Division of Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest University, Winston-Salem, North
Carolina; and 14Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins School of Medicine,
Baltimore, Maryland
ORCID IDs: 0000-0002-9718-9115 (R.M.B.); 0000-0003-1521-7520 (A.P.C.); 0000-0002-6968-4610 (M.B.D.).
Abstract
Rationale: Rural residence is associated with poor outcomes in
several chronic diseases. The association between rural residence
and chronic obstructive pulmonary disease (COPD) exacerbations
remains unclear.
Objectives: In this work, we sought to determine the independent
association between rural residence and COPD-related outcomes,
including COPD exacerbations, airflow obstruction, and symptom
burden.
Methods: A total of 1,684 SPIROMICS (Subpopulations and
Intermediate Outcome Measures in COPD Study) participants with
forced expiratory volume in 1 second/forced vital capacity , 0.70
had geocoding-defined rural-urban residence status determined
(N = 204 rural and N = 1,480 urban). Univariate and multivariate
logistic and negative binomial regressions were performed to assess
the independent association between rurality and COPD outcomes,
including exacerbations, lung function, and symptom burden.
The primary exposure of interest was rural residence, determined
by geocoding of the home address to the block level at the
time of study enrollment. Additional covariates of interest included
demographic and clinical characteristics, occupation, and
occupational exposures. The primary outcome measures were
exacerbations determined over a 1-year course after enrollment by
quarterly telephone calls and at an annual research clinic visit. The
odds ratio (OR) and incidence rate ratio (IRR) of exacerbations that
required treatment with medications, including steroids or
antibiotics (total exacerbations), and exacerbations leading to
hospitalization (severe exacerbations) were determined after
adjusting for relevant covariates.
Results: Rural residence was independently associated with a 70%
increase in the odds of total exacerbations (OR, 1.70 [95%
confidence interval (CI), 1.13–2.56]; P = 0.012) and a 46% higher
incidence rate of total exacerbations (IRR 1.46 [95% CI, 1.02–2.10];
P = 0.039). There was no association between rural residence and
severe exacerbations. Agricultural occupation was independently
associated with increased odds and incidence of total and severe
exacerbations. Inclusion of agricultural occupation in the analysis
attenuated the association between rural residence and the odds and
incidence rate of total exacerbations (OR, 1.52 [95% CI, 1.00–2.32];
P = 0.05 and IRR 1.39 [95% CI, 0.97–1.99]; P = 0.07). There was no
difference in symptoms or airflow obstruction between rural and
urban participants.
Conclusions: Rural residence is independently associated with
increased odds and incidence of total, but not severe, COPD
exacerbations. These associations are not fully explained by
agriculture-related exposures, highlighting the need for future
research into potential mechanisms of the increased risk of COPD
exacerbations in the rural population.
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Chronic obstructive pulmonary disease (COPD)
is a common condition worldwide, with a
prevalence estimated at 10% (1, 2). Acute
exacerbations of COPD (AECOPD) are a
major contributor to the morbidity and
mortality of the disease (3, 4). Reduced lung
function and a history of AECOPD are
established risk factors for future
development of AECOPD (5, 6). Persons
living in rural areas of the United States face
unique and important healthcare challenges.
They experience higher COPD mortality
rates than their urban counterparts across all
regions of the United States (7), and a
comparatively higher burden of chronic
diseases (8–10). The potential mechanisms
for poorer health outcomes in rural
populations include reduced access to care,
differential behavioral risk factors, and
unique environmental exposures. With
emergency department expenditures for
COPD increasing, limited access to care
among rural patients with COPD, and more
AECOPD-related morbidity and mortality in
the rural areas of the United States over
the preceding three decades, determining the
role rurality plays in AECOPD is important
(11–15). The impact of rural residence on
AECOPD has yet to be established in a
prospective, nationwide cohort.
SPIROMICS (Subpopulations and
Intermediate Outcome Measures in COPD
Study) is a multicenter, observational cohort
study of current and former smokers and
nonsmoking control subjects with extensive
physiologic, clinical, and biochemical
metrics (16). SPIROMICS affords the
opportunity to independently determine
associations between demographic factors
and COPD outcomes in a rigorous manner,
including access to geocoding for patient
residence and a robust assessment of
environmental and work exposures. For this
analysis, using home addresses obtained at
the time of enrollment, urban-rural status
was defined through geocoding to the block
level in individuals with COPD.
We hypothesized that rural residence
would be independently associated with an
increased risk of total and severe COPD
exacerbations. Rurality can impact COPD
outcomes through several mechanisms,
including environmental and occupational
exposures, socioeconomic status,
geographic location, smoking patterns,
and access to care. This study explores how
these factors impact the independent




SPIROMICS is a multicenter cohort study
that includes current and former smokers
(.20 pack years) and nonsmoking control
subjects between 40 and 80 years of age,
with and without COPD (defined as
postbronchodilator forced expiratory
volume in 1 second [FEV1]/forced vital
capacity [FVC] ratio , 0.70), who were
recruited from 12 clinical centers (16). The
analytical cohort for this study is limited to
SPIROMICS participants with spirometry-
defined COPD, complete 1-year exacerbation
data from the baseline visit, and rural-urban
residence status determined via geocoding as
described below (N = 1,684). Institutional
review boards at each center approved
SPIROMICS, and all participants provided
written informed consent.
Data Collection
Demographic data, smoking status and
history, inhaler mediation use, and
AECOPD occurrence in the year before the
baseline visit were obtained via self-report at
enrollment. Medical comorbidities were
defined via self-report of a physician’s
diagnosis. Respiratory symptom
assessments were performed using the
modified Medical Research Council
(mMRC) dyspnea scale (17); body mass
index, airflow obstruction, dyspnea, and
exercise (BODE) index (18); and COPD
assessment tool (CAT) (19). Chronic
bronchitis was defined using subdomains of
the St. George’s Respiratory Questionnaire
(20). All analyses incorporated
postbronchodilator spirometry data from
the baseline visit. Analyses of lung
computed tomography (CT) scans were
performed per protocols described
previously (21), including the extent of
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emphysema (defined as voxels below 2950
Hounsfield units) and functional small-
airways disease (22, 23) evaluated on a
whole-lung basis. Occupation and
occupational exposures were assessed by
asking the following questions: 1) have you
ever worked in a particular environment,
2) have you ever worked in a specific
occupation, and 3) in your job, do/did you
come into regular contact with any of the
following specific examples of vapors, gas,
dust, or fumes? A composite variable to
capture any agricultural exposure was
generated and defined as present with
an affirmative response to any of the
following questions: 1) have you ever had
a profession in agriculture, 2) have you
ever worked as a pig farmer, and 3) have
you ever been exposed to wheat, flower,
grain, animal feed, or cotton dust?
(24, 25).
The binary urban/rural classification
was determined from the 2010 U.S. Census.
The U.S. Census generally categorizes
census blocks as “urban” in areas containing
500 people per square mile and at least 2,500
people total (26), or “rural” otherwise.
Primary residency at the initial visit was
geocoded using the ArcGIS 10.3 system
(Esri), which is based primarily on parcel
data. Addresses that could not be
automatically geocoded (6% of the cohort)
were assigned based on a Google or Bing
Maps application search. Census data were
obtained from the U.S. Census via the
University of Washington library. The
demographic variable for rurality was
compiled at the block level using geocoded
addresses.
Longitudinal data on AECOPD were
collected by quarterly telephone calls and an
annual clinic visit. Two AECOPD outcomes
that occurred within the first year of study
follow-up were assessed as defined
previously (6, 27): 1) exacerbations
requiring treatment with medications,
including oral steroids or antibiotics (total
exacerbations), and 2) exacerbations that led
to an emergency department visit or
hospital admission (severe exacerbations).
Statistical Methods
Chi-square tests or t tests (for normally
distributed data) or the Kruskal-Wallis test
(for skewed data) were used to identify
differences in demographic and clinical
factors between rural and urban
participants. To determine the independent
association between rural residence
(exposure) and COPD exacerbations
(outcomes), logistic regression and
negative-binomial regression modeling
approaches were employed separately. For
logistic regression, exacerbations were
dichotomized as either no exacerbation or
any exacerbations over the first year after
enrollment, with odds ratios (ORs)
representing the odds of any exacerbation
related to exposure variables. For negative-
binomial regression models, exacerbations
were modeled continuously as the
number of exacerbations, with incidence
rate ratios (IRRs) representing the
incidence rate of an additional
exacerbation related to exposure variables.
For model construction, univariate
models were first constructed. Covariates
defined as clinically relevant from a
literature review or statistically associated
with outcomes of interest (threshold
P , 0.20) were included in multivariate
models. Sensitivity analyses were
performed to adjust for study site,
removal of previous exacerbation history
from models, and addition of the
agricultural occupation variable. A P value
, 0.05 was used to determine statistical




The total SPIROMICS cohort (N = 2,974)
included 1,831 individuals with spirometry-
confirmed COPD (FEV1/FVC , 0.7). The
analytical cohort included here comprised
1,684 participants with geocoding and
exacerbation data, representing 92% of the
COPD participants in SPIROMICS (see
Figure E1 in the online supplement). There
were no substantial differences in clinical
or demographic characteristics between
the analytical cohort and the larger cohort
of COPD participants in SPIROMICS
(Tables E1 and E2). Of the 1,684
SPIROMICS participants included in the
analysis, 204 (12%) resided in rural areas
and 1,480 (88%) resided in urban areas.
More than 20% of the enrolled patients at
four SPIROMICS centers (University of
Alabama-Birmingham, Wake Forest
University, University of Michigan at Ann
Arbor, and University of Iowa at Iowa City)
qualified as rural, constituting 81% of the
entire rural cohort. Rural participants were
more likely to be white and less likely to
have an annual income below $35,000
(Table 1). There was no difference in sex,
age, pack-years of smoking history, body
mass index (BMI), current smoking status,
or education between rural and urban
residents. Nonpulmonary medical
comorbidities were similar at baseline
(Table E3). Rural participants were more
likely to report ever being employed in
synthetic-fiber manufacturing, pig
farming, carpentry, agriculture, and beauty
care (Table E4). Rural participants
reported a higher prevalence of regular
contact with wheat flour or grain dust,
metal dust or fumes, cotton dust, and
animal feed (Table E5).
Association between Rural Residence
and COPD-related Outcomes
At the baseline visit, there was no difference
in measures of postbronchodilator FEV1
between rural and urban participants
(Table 2). Postbronchodilator FVC%
predicted was lower in rural participants
(85.5 vs. 89.2% predicted; P = 0.01). There
was no difference in the BODE index, CAT
scores, mMRC, or total count of AECOPD
requiring medications or severe
exacerbations in the 12 months before the
baseline visit between the groups. Self-report
of a physician’s diagnosis of asthma was less
prevalent among rural participants than
among urban ones (16% vs. 24%; P = 0.005),
whereas self-reported diagnosis of
emphysema, COPD, or chronic bronchitis
did not differ between the two groups.
Report of any inhaler use, short-acting
bronchodilator use, or long-acting inhaler
use did not differ between residence groups
(Table E6). There was no difference in CT
measures of emphysema or functional
small-airways disease between rural and
urban participants. Over the first year of
follow-up, there was no difference in the rate
of decline of FEV1 between rural and urban
participants (2516 213ml vs.2426 213ml;
P = 0.63).
As shown in Figure 1, in the 1 year after
follow-up from cohort entry, 78% of urban
patients had no exacerbations, whereas
14% had one, 4% had two, and 5% had
three or more AECOPD. Among the rural
cohort, 66% had no exacerbations, whereas
19% had one, 10% had two, and 5% had
three or more AECOPD (overall chi-square
P = 0.002). For severe exacerbations, 91%
of the urban participants had no severe
exacerbations, 6% had one, 2% had two,
and 1% had three or more severe AECOPD.
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In the rural cohort, 88% had no severe
exacerbations, whereas 10% had one, 1%
had two, and 1% had three or more severe
exacerbations (overall chi-square P = 0.37).
There was no difference in severe
exacerbations between rural and urban
participants who experienced an
exacerbation during follow-up (34%
vs. 36%; P = 0.71).
Association between Rural Residence
and Total Exacerbations
In univariate logistic regression, several
factors were associated with increased
odds of total exacerbations (Table E7).
These included never having graduated
from high school, a reported history of
asthma, lower baseline FEV1, and a history
of two or more exacerbations in the year
before enrollment. Older age and male
sex were associated with reduced odds of
total AECOPD. In a univariate analysis,
rural residence was associated with an 81%
increase in the odds of total exacerbations
(OR, 1.81 [95% CI, 1.32–2.47]; P , 0.001).
A multivariate logistic regression model
was generated that included age, race, sex,
current smoking status, education,
income, asthma history, baseline FEV1,
number of exacerbations in the year
preceding enrollment, and rural status
(Table 3). In this model, white race,
reported history of asthma, lower baseline
FEV1, younger age, and two or more
exacerbations in the year preceding
enrollment were associated with
significantly increased odds of total
exacerbations. Rural residence was
independently associated with a 70%
increase in odds of total AECOPD (OR,
1.70 [95% CI, 1.34–2.56]; P = 0.012).
Using negative binomial regression
modeling, factors associated with an
increased incidence rate of total AECOPD in
the univariate analysis included not
graduating from high school, reduced FEV1,
two or more exacerbations in the year before
enrollment, yearly income less than $50,000,
and history of asthma (Table E7). Older age
and male sex were associated with a lower
incidence of total exacerbations. In a
univariate analysis, rural residence was
associated with a 46% increase in the
incidence rate of total exacerbations (IRR,
1.46 [95% CI, 1.06–2.00]; P = 0.02).
In a multivariate analysis (Table 3)
incorporating the same covariates as in
the logistic regression models, an increased
incidence rate of total exacerbations was
seen with white race, reported history of
asthma, lower baseline FEV1, younger
age, and two or more exacerbations in
the year before enrollment. Rural
residence was independently associated with
a 46% higher incidence rate of total
exacerbations (IRR, 1.46 [95% CI, 1.02–
2.10]; P = 0.039).
Association between Rural Residence
and Severe Exacerbations
In univariate logistic regression, several
factors were associated with severe
AECOPD (Table E8). These factors
included not graduating from high school,
yearly income less than $50,000, lower
baseline FEV1, reported history of asthma,
and having two or more exacerbations in the
year before enrollment. Factors associated
with lower odds of severe exacerbation
included older age and white race. Rural
residence was not associated with
differential odds of severe exacerbation
(OR, 1.38 [95% CI, 0.88–2.17]; P = 0.16). In
multivariate logistic regression (Table 4),
only a low baseline FEV1 and not graduating
from high school were associated with
an increased odds of severe exacerbation.
Rural residence was not associated with
odds of severe exacerbation at 1-year follow-
up (OR, 1.15 [95% CI, 0.63–2.11]; P = 0.66)
in a multivariate analysis.
Using negative binomial regression
modeling, factors associated with an
increased incidence rate of severe
exacerbations in a univariate analysis (Table
E8) included not graduating from high
school, annual income of less than $50,000,
reported history of asthma, lower baseline
FEV1, and two or more exacerbations in the
year before enrollment. Factors associated
with a reduced incidence rate of severe
exacerbations in univariate analysis
included age and white race. Rural
residence was not associated with an
increased incidence rate of severe
exacerbations in the univariate analysis
(IRR, 1.09 [95% CI, 0.65–1.83]; P = 0.75). In
multivariate negative binomial regression
(Table 4), lower baseline FEV1 was
independently associated with a higher
incidence of severe exacerbations. Rural
residence was not independently associated
with an increased incidence rate of severe
exacerbations (IRR, 1.14 [95% CI, 0.60–
2.17]; P = 0.68).
Table 1. Cohort demographic and clinical characteristics
n Urban 1,480 Rural 204 P Value
Age, yr 65.3 (8.1) 65.4 (7.2) 0.89
Race ,0.001
White 1175 (79) 200 (98)
Black 244 (16) 1 (0)
Asian 22 (1) 0 (0)
American Indian 7 (0) 0 (0)
Mixed 23 (2) 3 (1)
Missing 9 (1) 0 (0)
Female 622 (42) 96 (47) 0.17
Body mass index, kg/m2 27.3 (5.3) 27.5 (4.9) 0.73
Pack-years smoked 52.5 (26.6) 54.0 (23.8) 0.16
Current smoker 490 (34) 66 (33) 0.78
Education 0.12
Eighth grade or below 25 (1) 6 (3)
Trade/business/some high school 154 (10) 24 (12)
High school graduate 374 (25) 56 (27)
Trade/business after high school 73 (5) 16 (8)
Some college 444 (30) 64 (31)
Bachelor’s degree 190 (13) 21 (10)
Post-Bachelor’s education 215 (15) 17 (8)
Declined to answer 2 (0) 0 (0)
Total yearly income 0.005
,$15,000 255 (17) 35 (17)
$15,000–$34,999 310 (21) 28 (14)
$35,000–$49,999 179 (12) 38 (19)
$50,000–$74,999 212 (14) 36 (18)
$75,0001 260 (18) 24 (12)
Declined to answer 250 (17) 42 (21)
All values are mean (SD) or n (%) unless otherwise indicated.
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Impact of Agricultural Exposures on
COPD Exacerbations and
Rural Associations
Because substantial differences in
occupation and occupational exposures
were associated with rurality, a composite
agricultural exposure variable was generated
(see METHODS). The prevalence of
agriculture exposure was higher in rural
compared with urban participants (25% vs.
12%; P , 0.001). In a univariate analysis,
agricultural exposure was associated with
increased odds (OR, 1.60 [1.19–2.15];
P = 0.002) and incidence (IRR, 1.75
[1.30–2.36]; P , 0.001) of total
exacerbations. Agriculture exposure was
also associated with increased odds
(OR, 1.82 [1.16–2.85]; P = 0.009) and
incidence (IRR, 1.94 [1.30–2.89];
P = 0.001) of severe exacerbations. Inclusion
of agricultural exposure in multivariate
models demonstrated that agriculture
exposure was independently associated
with increased odds (OR, 2.18 [95% CI,
1.51–3.16]; P , 0.001) and incidence
(IRR, 1.53 [95% CI, 1.11–2.11]; P = 0.01)
of total exacerbations (Table E9).
Agricultural exposure was also independently
associated with increased odds (OR, 2.23
[95%CI, 1.36–3.56]; P = 0.002) and incidence
(IRR, 2.00 [95% CI, 1.20–3.33]; P = 0.01) of
severe exacerbations. Addition of agricultural
exposure to the multivariate analysis
attenuated the association between rural
residence and increased odds of total
exacerbations (OR, 1.52 [95% CI, 1.00–2.32];
P = 0.05) and the incidence rate of total
exacerbations (IRR, 1.39 [95% CI, 0.97–1.99];
P = 0.07).
Sensitivity Analysis
The association between rural residence and
total exacerbations was attenuated with
inclusion of study site (OR, 1.30 [95% CI,
0.84–2.01]; P = 0.24; and IRR, 1.21 [95% CI,
0.84–1.76]; P = 0.31). Restricting analysis to
the four sites with the highest rural
prevalence attenuated the association
between rural residence and total
exacerbations (OR, 1.33 [95% CI, 0.81–
2.17]; P = 0.26; and IRR, 1.35 [95% CI, 0.92–
1.97]; P = 0.12). Inclusion of a metal dust/
fume exposure variable did not alter the
rural associations, and in these models,
metal fumes were not significantly
correlated with AECOPD. Inclusion of prior
exacerbation history could overadjust for
future exacerbations. In multivariate models
excluding prior exacerbation history, rural
residence remained independently
associated with increased odds (OR, 1.68
[95% CI, 1.18–2.39]; P = 0.004) and
incidence (IRR, 1.42 [95% CI, 1.03–1.95];
P = 0.031) of total exacerbations. Rurality
remained unassociated with severe
exacerbations in all sensitivity models.
Smoking history measured by pack-years
was not independently associated with total
exacerbations (P = 0.33 for logistic
regression and P = 0.4 for negative binomial
model) or severe exacerbations (P = 0.90 for
logistic regression and P = 0.85 for negative
binomial model). Given the difference in
income categories at enrollment,
multivariate models incorporating income
with five categories were generated. These
models did not impact the associations
between rural status and total exacerbations,
nor was income statistically significant in
these models. There was no impact of
alternative income covariate modeling on
the lack of a rural association with increased
odds of severe exacerbations. In negative
Table 2. Baseline pulmonary function and chronic obstructive pulmonary disease
symptom characteristics
Urban Rural P Value
FEV1/FVC, postbronchodilator 67.4 (17.5) 68.5 (16.6) 0.40
FEV1, postbronchodilator
Absolute, L 1.75 (0.80) 1.70 (0.68) 0.30
% predicted 61.4 (23.4) 59.6 (20.6) 0.25
FVC, postbronchodilator
Absolute, L 3.37 (1.08) 3.26 (0.93) 0.15
% predicted 89.2 (20.5) 85.5 (17.3) 0.005
GOLD category* 0.34
A 353 (24) 59 (29)
B 545 (37) 70 (34)
C 87 (6) 8 (4)
D 486 (33) 67 (33)
CAT score, median (IQR) 15 (12) 15 (11) 0.84
CAT score >10 1,035 (73) 137 (71) 0.67
Chronic bronchitis by SGRQ 650 (46) 101 (53) 0.09
mMRC, median (IQR) 1 (1) 1 (2) 0.28
mMRC > 2 465 (32) 63 (31) 0.83
BODE index 2.08 (2.1) 1.95 (1.7) 0.23
Total COPD exacerbations in prior 12 mo 0.59
0 1,043 (72) 139 (70)
1 213 (15) 35 (18)
21 184 (13) 25 (13)
Severe COPD exacerbations in prior 12 mo 0.73
0 1,233 (84) 168 (83)
1 158 (11) 23 (11)
21 69 (5) 12 (6)
Patient-reported physician diagnosis of chronic
bronchitis
374 (27) 53 (27) 0.96
Patient-reported physician diagnosis of
emphysema
697 (50) 97 (49) 0.70
Patient-reported physician diagnosis of COPD 1,086 (76) 144 (72) 0.14
Patient-reported physician diagnosis of chronic
bronchitis, emphysema, or COPD
1,193 (84) 158 (79) 0.091
Diagnosis of asthma 348 (25) 30 (16) 0.005
Diagnosis of asthma as a child 144 (10) 14 (7) 0.19
Diagnosis of asthma as an adult 196 (14) 15 (8) 0.018
Asthma status 0.014
Current asthma 251 (19) 19 (10)
Past asthma 58 (4) 6 (3)
Never asthma 1,043 (77) 160 (86)
Definition of abbreviations: BODE = body mass index, airflow obstruction, dyspnea, exercise; CAT =
COPD Assessment Test; COPD = chronic obstructive pulmonary disease; FEV1 = forced expiratory
volume in 1 second; FVC = forced vital capacity; GOLD =Global Initiative for Obstructive Lung Disease;
IQR = interquartile range; mMRC = modified Medical Research Council; SGRQ = St. George’s
Respiratory Questionnaire.
All values are mean (SD) or n (%) unless otherwise indicated.
*GOLD categorization using COPD Assessment Test criteria.
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binomial modeling, only the highest income
category compared with the lowest was
associated with a reduced incidence of
severe exacerbations (IRR, 0.33 [95% CI,
0.14–0.75]; P = 0.008).
Discussion
In this analysis of individuals with
spirometry-confirmed COPD participating
in the observational SPIROMICS cohort, we
observed that rural residence was
independently associated with increased
odds and incidence of AECOPD requiring
treatment, but not severe exacerbations
requiring an emergency room visit or
hospitalization. Rural residence
independently conferred a 70% increase in
the odds and a 46% increase in the incidence
of total AECOPD. The association between
rural residence and exacerbation risk
persisted after we accounted for potential
confounders, including smoking patterns,
lung function, prior exacerbation history,
and income. Rural residence was associated
with agriculture-related exposures; however,
the association between rural residence and
exacerbation risk was not fully explained
after we accounted for agriculture-related
exposures.
Investigations of rural healthcare
outcomes in the United States have
described disparate outcomes in chronic
diseases such as heart disease, stroke, and
cancer (28–30). From 1980 to 2014, the rates
of mortality from chronic respiratory
disease have increased, as illustrated by
COPD-related deaths in the rural locales of
central Appalachia (15). Rural patients with
COPD across the United States have more
frequent hospitalizations, more severe
dyspnea, worse quality of life, and access to
fewer pulmonary specialists (7, 12, 13, 31–
34). Rural patients in the Veterans Affairs
system have been shown to have increased
mortality related to acute exacerbations
(14). Furthermore, patients in rural and
urban hospitals experience differential
outcomes (35). The adverse pulmonary
outcomes seen in rural patients with COPD
are due to multiple factors, including a lack
of adequate diagnoses and treatments,
differential access to acute and chronic
care, and limited availability of pulmonary
specialists (13). This study extends
previous investigations by demonstrating
that rural status is independently
associated with more frequent COPD
exacerbations requiring treatment. This
finding persisted after we accounted for
medication use patterns, comorbidities,
and markers of socioeconomic status that
are often implicated in health outcome
disparities in rural populations. Although
income did differ between rural and urban
participants, we observed no consistent
association between income and AECOPD
or the impact of income on rural
associations with AECOPD. Poor access to
healthcare is often implicated as a cause of
adverse health outcomes in chronic
disease, as demonstrated by the increased
rate of hospital readmissions for patients
with heart failure who do not have ready
access to healthcare due to rurality (36).
However, the participants enrolled in
SPIROMICS may have been less subject to
limited access than the general rural
population given their involvement in a
study at an academic center. Thus, the
RuralUrban






























Figure 1. Percentage of urban (blue bars) and rural (red bars) SPIROMICS participants experiencing total (A) or severe (B) COPD exacerbations within the
first year of study follow-up. Overall chi-square P = 0.002 (total) and P = 0.37 (severe) exacerbations. COPD= chronic obstructive pulmonary disease.
Table 3. Multivariate regression models* for chronic obstructive pulmonary disease
total exacerbations in the first 365 days of follow-up
Logistic Regression Negative Binomial Regression
OR (95% CI) P Value IRR (95% CI) P Value
Age (per 10 yr) 0.69 (0.57–0.84) ,0.001 0.74 (0.62–0.88) 0.001
White race (vs. others) 1.79 (1.19–2.68) 0.005 1.74 (1.23–2.46) 0.002
Male 1.19 (0.88–1.63) 0.27 1.06 (0.81–1.39) 0.68
Current smoking 0.77 (0.55–1.08) 0.13 0.95 (0.71–1.26) 0.71
Not graduating high school 1.32 (0.86–2.01) 0.20 1.32 (0.92–1.89) 0.13
Income , $50,000 1.03 (0.75–1.42) 0.84 1.05 (0.8–1.39) 0.71
History of asthma 1.53 (1.11–2.12) 0.011 1.49 (1.12–1.98) 0.006
Baseline FEV1 (per 100 ml) 0.93 (0.91–0.95) ,0.001 0.93 (0.91–0.95) ,0.001
More than two exacerbations
at baseline
3.03 (2.11–4.36) ,0.001 2.71 (2–3.68) ,0.001
Rural residence 1.70 (1.13–2.56) 0.012 1.46 (1.02–2.10) 0.039
Definition of abbreviations: CI = confidence interval; FEV1 = forced expiratory volume in 1 second;
IRR = incidence rate ratio; OR = odds ratio.
*Adjusted for all covariates in the table.
ORIGINAL RESEARCH
Burkes, Gassett, Ceppe, et al.: Rural Residence and COPD Exacerbations 813
 
estimates of association between rurality
and COPD outcomes in SPIROMICS
may underestimate the strength of
associations in the general rural
population.
Environmental exposures may explain
the association between rural residence and
increased AECOPD risk. Globally, exposure
to biomass fuel is associated with respiratory
symptoms and poor pulmonary function
(37). Individuals in professions with a high
risk of exposure based on job exposure
matrices have been shown to have more
episodes of AECOPD requiring emergency
department care and hospital admission (38,
39). Agricultural work produces dusts and
vapors that can cause and/or exacerbate
underlying lung disease (40, 41).
Agricultural workers may be exposed to
ambient gasses and particles such as
ammonia, pesticides, bacterial products
(including peptidoglycan and endotoxin),
and fungal spores, which collectively play a
role in the development of COPD and
respiratory symptoms (39, 40, 42). Specific
farm-animal exposures may impair
respiratory health. Swine farm practices over
the last few decades have been associated
with worsening respiratory symptoms (43,
44). Exposure to poultry and livestock has
been shown to increase the risk of COPD
(45) and worsen respiratory symptoms (46,
47). Higher exposure to indoor endotoxin is
also associated with reduced lung function
in the U.S. farming population (48). Rural
populations may be exposed to an increased
load of ambient endotoxin and small
particulate matter that may increase
respiratory symptoms in patients with
COPD (49, 50). The exposure profiles of the
rural participants in SPIROMICS were
substantially different from those of their
urban counterparts, and agricultural
exposures were statistically associated with
AECOPD, suggesting that these exposures
may underlie some of the increased
exacerbation risk. FVC was also reduced in
rural participants. This reduction, which
was not explained by differences in BMI,
may represent early interstitial changes
associated with chronic respiratory
exposures.
The findings presented here confirm
the results of prior studies of AECOPD risk
factors, including reduced FEV1 and
previous exacerbation history (6, 51–56).
Although white race was also associated
with an increased exacerbation risk, the
underrepresentation of other racial groups
limits interpretation of these findings.
Older age was associated with a reduced
risk of total and severe AECOPD in this
analysis. There are several potential
explanations for this association: 1) in this
cohort, older individuals had fewer
exacerbations in the year before enrollment
and less severe airflow obstruction, and
were less likely to be current smokers; 2)
younger participants may have better
functional status, allowing them to work in
the agricultural sector and thereby
increasing their exposure profile; 3) the
older population in this study may
represent a “survivor” population with
overall better health; and 4) the availability
of Medicare insurance to the elderly may
afford these patients better access to care
and reduce the risk of exacerbations (57).
Although rural participants
experienced more overall exacerbations
than urban participants, severe
exacerbations did not differ between these
groups. There are several potential
explanations for this observation. First,
the factors associated with increased
exacerbation rates in rural participants
(i.e., agricultural exposures) may lead to
milder exacerbation severity. Second,
differential access to care among rural
participants could lead to fewer hospital
encounters, which are required to meet
the criteria for severe exacerbation. Finally,
this observation may be explained by
the low overall prevalence of severe
exacerbations in SPIROMICS, leading
to insufficient power to detect this
difference.
This study has several limitations.
Although the reported data support the
conclusion that agricultural exposures
substantially contribute to pulmonary
outcomes in rural participants, we are
not able to fully determine the potential
impact of access to healthcare on rural
participants. We do not have robust data
regarding health insurance at the time of
recruitment or at younger ages. Because
recruitment occurred primarily in urban
academic medical centers, rural
participants may have been required to
travel to these centers for participation.
We do not have data on distance from
residence to recruitment center. However,
participant enrollment suggests access to
the recruiting medical centers. This
mobility may not be reflective of a broader
rural population. Alternatively, rural
participants may have resided closer to
urban centers, resulting in characteristics
that more closely resemble urban
individuals. These selection factors may
result in a biased cohort of rural
individuals who may not be representative
of the larger U.S. rural population.
Although this is supported by
demographic similarities between the
cohorts, agricultural and occupational
profiles did differ between rural and urban
participants. The impact of rural
participants being more urbanized would
attenuate any observed associations. In a
more representative rural population,
observed differences in pulmonary
outcomes may be greater. Although there
was no observed association between self-
reported income and pulmonary
outcomes, this metric may not accurately
Table 4. Multivariate regression models* for severe chronic obstructive pulmonary
disease exacerbations in the first 365 days of follow-up
Logistic Regression Negative Binomial Regression
OR (95% CI) P Value IRR (95% CI) P Value
Age (per 10 yr) 0.78 (0.60–1.02) 0.07 0.79 (0.60–1.03) 0.085
White race (vs. others) 0.85 (0.52–1.39) 0.52 0.98 (0.59–1.63) 0.93
Male 1.32 (0.86–2.02) 0.21 1.37 (0.88–2.12) 0.16
Current smoking 0.97 (0.61–1.54) 0.89 1.01 (0.64–1.61) 0.95
Not graduating high school 1.83 (1.09–3.07) 0.022 1.36 (0.78–2.38) 0.28
Income , $50,000 1.32 (0.82–2.13) 0.25 1.58 (0.98–2.55) 0.06
History of asthma 1.24 (0.79–1.94) 0.36 1.49 (0.94–2.36) 0.09
Baseline FEV1 (per 100 ml) 0.91 (0.88–0.95) ,0.001 0.90 (0.87–0.94) ,0.001
More than two exacerbations
at baseline
1.54 (0.95–2.51) 0.083 1.55 (0.93–2.58) 0.091
Rural residence 1.15 (0.63–2.11) 0.66 1.14 (0.60–2.17) 0.68
Definition of abbreviations: CI = confidence interval; FEV1 = forced expiratory volume in 1 second;
IRR = incidence rate ratio; OR = odds ratio.
*Adjusted for all covariates in table.
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reflect expendable income, as living wages
differ across multiple U.S. geographic
regions. The relatively low number of
rural participants and low exacerbation
rates in this cohort may limit the power
to detect a true association between
rural residence and severe exacerbations.
Self-reported data elements (exacerbation
data, comorbidities, and medication use)
are susceptible to recall bias. Occupational
exposures were assessed as ever-exposure,
but did not include the duration of
exposure or current exposure status and
may not fully reflect cumulative
occupational exposures. It is possible that
the geographical location in the country
may impact some of our observed
associations. This is supported by the
attenuation of our observations when we
adjusted for site. However, the site variable
likely encompasses many confounders
relevant to the rural-COPD relationship
(geographic location, exposures, and
access to care), making this attenuation
somewhat nonspecific. As geocoding was
performed only on baseline residence, this
analysis does not account for geographic
migration during follow-up.
In conclusion, we have observed that
rural residence is associated with an
increased risk of COPD exacerbations
requiring treatment. Agriculture-related
exposures were more prevalent in rural
populations and strongly associated with
an increased risk of COPD exacerbations,
but did not fully explain the association
between rural residence and COPD
exacerbations. Through these findings, this
study advances our understanding of the
impact of rural residence on COPD
exacerbations and identifies areas of
further investigation into the prevention
of pulmonary symptoms in rural patients
with COPD. These findings highlight the
need for robust epidemiological cohorts
to investigate within the rural COPD
population factors such as access to
healthcare, the impact of regional air
pollution and particulate matter, the
influence of longitudinal agricultural
exposures, and potential biomarkers and
radiographic parameters specific to rural
populations. n
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52 Margüello MS, Garrastazu R, Ruiz-Nuñez M, Helguera JM, Arenal S,
Bonnardeux C, et al. Independent effect of prior exacerbation frequency
and disease severity on the risk of future exacerbations of COPD: a
retrospective cohort study. NPJ Prim Care Respir Med 2016;26:16046.
53 Tomioka R, Kawayama T, SuetomoM, Kinoshita T, Tokunaga Y, Imaoka
H, et al. “Frequent exacerbator” is a phenotype of poor prognosis in
Japanese patients with chronic obstructive pulmonary disease. Int J
Chron Obstruct Pulmon Dis 2016;11:207–216.
54 Make BJ, Eriksson G, Calverley PM, Jenkins CR, Postma DS, Peterson
S, et al. A score to predict short-term risk of COPD exacerbations
(SCOPEX). Int J Chron Obstruct Pulmon Dis 2015;10:201–209.
55 Flattet Y, Garin N, Serratrice J, Perrier A, Stirnemann J, Carballo S.
Determining prognosis in acute exacerbation of COPD. Int J Chron
Obstruct Pulmon Dis 2017;12:467–475.
56 Zider AD, Wang X, Buhr RG, Sirichana W, Barjaktarevic IZ, Cooper CB.
Reduced COPD exacerbation risk correlates with improved FEV1: a
meta-regression analysis. Chest 2017;152:494–501.
57 Simmering JEPL, Polgreen LA, Comellas AP, Cavanaugh JE, Polgreen
PM. Identifying patients with COPD at high risk of readmission.
Chronic Obstr Pulm Dis (Miami) 2016;3:729–738.
ORIGINAL RESEARCH
816 AnnalsATS Volume 15 Number 7| July 2018
 
